TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of 1 of the following:~  * Myelodysplastic syndromes (MDS)~    * International Prognostic Scoring System (IPSS) score ≥ intermediate-2~ * Chronic myelomonocytic leukemia~ * Acute myeloid leukemia arising from MDS~* Must have failed or are ineligible for or intolerant to treatment with azacitidine~  * Patients with normal marrow cytogenetics or an isolated 5q- abnormality must have failed or are ineligible for or intolerant to treatment with lenalidomide~ * Patients who are HLA-DR15-positive must have failed or are ineligible for pharmacologic immunosuppression (e.g., anti-thymocyte globulin, cyclosporine, steroids)~* No presence of cytotoxic antibodies against donor lymphocytes~* No HLA-identical donor available OR ineligible for HLA-identical allogeneic bone marrow transplantation~* HLA partially mismatched (haploidentical) related donor available~  * First-degree related donor, including half-siblings or first cousins~ * Inherited recombinant haplotype from parents allowed if donor shares ≥ 1 HLA antigen at each of the HLA-A, -B, and DR loci~PATIENT CHARACTERISTICS:~* ECOG performance status (PS) 0-1 OR Karnofsky PS 80-100%~* Bilirubin \< 3.0 mg/dL~* AST and ALT ≤ 4 times upper limit of normal~* Creatinine \< 3.0 mg/dL~* LVEF \> 35%~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from prior therapy~* No prior transfusions from donor~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy~* No other concurrent investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide + T cells (Type: EXPERIMENTAL): Conditioning regimen with cyclophosphamide followed by donor T cells on Day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Enteral Nutrition and Glycemic Variability Neurological Intensive Care Unit Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged between 18 and 89 years old~* Patients with critical illness including ischemic or hemorrhagic stroke, epidural/subdural bleeds and subarachnoid hemorrhage~* Patients who are expected to stay in the ICU for at least 5 days~* Hyperglycemia is not an inclusion criteria~Exclusion Criteria:~* Patients who have received or will be treated with systemic corticosteroids.~* Patients who will be receiving high doses of propofol (\>40 cc/hr)~* Patients with type 1 Diabetes~* Patients with sepsis or acute trauma~* Patients with an expected stay in the ICU of less than 4 days~* Patients who are unable to receive enteral nutrition or who have medical conditions precluding nutrition by the enteral route including allergies to formula components~* Pregnant and lactating patients~* Patients with prior history of gastroparesis~* Patients with acute kidney failure (creatinine \> 2.5mg/dl)~* Patients with acute liver failure (bilirubin \> 2.0 mg/dl)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Glycerna (Type: EXPERIMENTAL): Diabetic specific formula. The volume /rate of glycerna will be determined by the dietician according to standard formula.
- Control - Jevity (Type: ACTIVE_COMPARATOR): The control arm of the study. Patients to receive Jevity. The volume /rate of Jevity will be determined by the dietician according to standard formula.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Death Rattle - A Double Blind, Randomly Controlled, Crossover Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* : Patients belonging to Home Palliative Care Unit of Clalit Health Services - Southern District, and the Oncology Department of Soroka University Medical Center and suffering from death rattle will be recruited for the study.~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of an Early Support Programme in Orthophony

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premature birth \< 32 weeks of amenorrhea~* or premature birth with intrauterine growth restriction (IUGR) \< P3~* corrected age ≤ 6 months at the time of inclusion~* affiliation to a social security system + mutual insurance~Exclusion Criteria:~* genetic pathology~* ongoing developmental care: psychomotricity or speech therapy~* neuromuscular pathology affecting oral and facial motor skills~* severe oral disorders: feeding by gastric tube or gastrostomy~* severe sensory, auditory or visual impairment~* neither of the 2 French-speaking parents

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- Early Support Programme in Orthophony (Type: EXPERIMENTAL): Early support in speech therapy lasts between 6 months and 24 months of corrected age. It includes 10 to 20 sessions depending on the child's needs. These sessions are conducted by a speech-language pathologist from the RPSOF-ASNR network, trained in the issues specific to the very premature child and the network's tools.
- Standard Care (Type: NO_INTERVENTION): Standard follow-up within the RPSOF-ASNR network, without systematic speech therapy sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Negative Pressure Wound Therapy for the Treatment of Chronic Pressure Wounds

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 18 years~2. All chronic pressure wounds of the pelvic region except trochanteric wounds.~3. Chronic pressure wound defined as the presence of a pressure wound for \> 6 weeks and \< 6 months with no sign of improvement in healing~4. Wound size surface area \> 2cm2~5. Stage III-IV pressure ulcer according to the National Pressure Ulcer Advisory Panel (NPUAP)~6. No clinical signs of active infection at the wound site and currently not on antibiotics~7. Willingness to off-load or pressure redistribute ulcer~Exclusion Criteria:~1. Candidate for surgery in the next 12 weeks~2. A wound with necrotic tissue unable to tolerate debridement~3. Exposed blood vessels and/or organs within the wound~4. Chronic osteomyelitis (as determined by biopsy) or osteomyelitis that is not treatable by debridement and antibiotics~5. Non-enteric or unexplored fistulae~6. Wounds requiring hemostasis (i.e., that the flow of blood be stopped) for local bleeding~7. Alternate etiology for non-healing~8. Concomitant conditions that in the judgment of the investigator would make the subject inappropriate for entry to the study (e.g., malignancy in wound, malignancy less than 1-year disease free interval, previous or current irradiation, known immunodeficiency and/or major uncorrected medical disorders such as serious non-malignant disease, serious cardiovascular or pulmonary disease, lupus, inflammatory bowel disease, palliative care or sickle cell disease)~9. Poor nutritional status as determined by a Braden Scale Nutritional Assessment score of 2 or 1 with a serum albumin \< 25 g/L and hemoglobin \< 90 g/L~10. Currently taking medication that may interfere with wound healing (e.g., oral systemic steroids, immunosuppressive drugs, unfractionated heparin infusion)~11. Women who are currently pregnant or are breast feeding; or women of child bearing potential who are not currently taking adequate birth control~12. Participation in another investigative drug or device trial currently or within the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Standard Dressings
- 2 (Type: EXPERIMENTAL): Negative Pressure Wound Therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preventing Chronic Post Surgical Pain After Limb Surgery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Trauma patient undergoing orthopedic surgery for upper extremity or shoulder~2. Age \>18 and \< 75 years~3. Both males and females~4. Understand English (reading, writing and speaking)~5. Patient gives a written consent for being involved in this study~Exclusion Criteria:~1. Patient with any sort of chronic pain including fibromyalgia~2. Patient using opioids for \>90 days~3. Patient who had an associated injury related to the trauma apart from that limb~4. Patient who need more than one surgery to fix the problem~5. Patient diagnosed with major depression~6. Failed or partially effective block~7. Bilateral surgical intervention

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- study (first group) (Type: EXPERIMENTAL): The first group will include those who receive a single shot brachial plexus block with or without general anesthesia.
- Controlled (second group) (Type: NO_INTERVENTION): The second group will be the control group and include those patients who receive general anesthesia only, without any block whether due to the preference of patient or the surgeon.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Central Mechanisms That Regulate Glucose Metabolism in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers~Exclusion Criteria:~* Hyperlipidemia~* Hypertension~* Heart disease~* Cerebrovascular disease~* Seizures~* Bleeding disorders~* Muscle disease

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Diazoxide (Type: ACTIVE_COMPARATOR): 1-2 mg/kg total dose given intravenously during pancreatic clamp study
- Placebo (Type: PLACEBO_COMPARATOR): Intravenous normal saline during pancreatic clamp study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Feasibility of a Non-invasive Wearable Acoustic Device for Measuring Air Trapping in COPD

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria for cases (COPD patients) are:~1. Men or women over 40 years old.~2. Spirometric COPD.~3. A history of smoking at least 20 pack-years.~Exclusion Criteria:~1. Inability to perform lung function testing.~2. Inability to complete the study and return for follow-up visits.~3. Pregnancy.~4. A serious and active heart condition, defined by stable or unstable angina, recent myocardial infarction (within the last 2 years), active or decompensated congestive heart failure or cardiomyopathy.~5. End-stage liver disease.~6. Patients unable to do mild exercise (patients with orthopedic-neurologic problems; patients who have severe heart failure characterized by an ejection fraction of \<20% or by New York Heart Association Class IV disease; patients who should be at complete rest, confined to a bed or chair; or patients for whom physical activity brings on discomfort and for whom symptoms occur at rest).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Cases with Air Trapping (Type: None): 20 COPD patients with lung volumes representing air trapping (RV/TLC and functional residual capacity to TLC \[FRC/TLC\])
- Cases without Air Trapping (Type: None): 20 COPD patients without lung volumes representing air trapping (RV/TLC and functional residual capacity to TLC \[FRC/TLC\])
- Healthy Controls (Type: None): Non COPD patients and non-smokers

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preliminary Study to the Manufacturing of a Non-stick Membrane for Surgery Using Patient's Own Cells (MESO-PATCH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged more than 18 years old,~* Planned surgery For peritoneal samples : abdominal surgery (laparotomy or coelioscopy) For adipose tissue samples : breast reconstructive surgery (lipomodelage)~* Informed and signed consent~Exclusion Criteria:~* Pregnant or breastfeeding woman~* Patient under guardianship or tutorship~* For peritoneal samples : previous abdomino-pelvic radiotherapy or abdominal surgery ; peritoneal carcinosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biological samples collection (Type: EXPERIMENTAL): -Peritoneal samples : will be collected during abdominal surgery~A biopsy from 1 to 2 cm2 will be performed in healthy peritoneum~-Adipose tissue samples : will be collected during surgery for breast reconstruction

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years and older and premenopausal (based on gynecological history i.e. still menstruating; no significant estrogen deficiency symptoms)~* Diagnosis of uterine fibroids documented by ultrasound and relevant symptoms reported by the patient (e.g. heavy menstrual bleeding, pelvic pressure)~* Patients for whom surgery (hysterectomy or myomectomy) for the treatment of symptomatic uterine fibroids is planned~* Patients who are otherwise healthy as shown by medical history, physical and gynecological examinations, and laboratory test results~Exclusion Criteria:~* Contraindications for the progesterone receptor modulators (PRM) vilaprisan or ulipristal acetate~* Use of medication that might interfere with the conduct of the study or the interpretation of the results (e.g. continuing use of hormonal contraceptives, tranexamic acid or other treatments for heavy menstrual bleeding, progesterone receptor modulators, gonadotropin-releasing hormone agonist, anticoagulants, moderate and strong CYP3A4 inducers and moderate and strong CYP3A4 inhibitors within a defined time period before treatment starts.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vilaprisan group (Type: EXPERIMENTAL): Vilaprisan 2 mg oral daily over 8-12 weeks
- Ulipristal group (Type: ACTIVE_COMPARATOR): Ulipristal 5 mg oral daily over 8-12 weeks
- Control group (Type: NO_INTERVENTION): Patients undergoing surgery without any prior treatment, as control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Proton Pump Inhibitor Plus Propranolol Versus Proton Pump Inhibitor Alone on Peptic Ulcer Healing in Patients With Liver Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 20 and 85 years old~* Liver cirrhosis associated with esophageal varices or gastric varices~* Gastric ulcer or duodenal ulcer ,size bigger or egual than 0.5 cm~Exclusion Criteria:~* Acute bleeding~* Steroid or NSAID user~* Pregnancy, or the patients with other terminal illness (such as other terminal cancers, heart failure, renal failure...)~* Propranolol contraindications (such as atrioventricular block, heart failure, chronic obstructive pulmonary disease, asthma, poorly controlled diabetes, severe peripheral arterial disease...)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Proton-pump inhibitor (Type: PLACEBO_COMPARATOR): PPI: Pariet EC 20 mg/QDAC
- Propranolol+Proton-pump inhibitor (Type: ACTIVE_COMPARATOR): Propranolol:~Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate\>55 or systemic blood pressure\>90mmHg)~PPI: Pariet EC 20 mg/QDAC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Analysis of Natural Killer Cell Activity (NKA) in Whole Blood in High Risk Subjects Undergoing Colonoscopy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subjects aged 40 and over who are scheduled to undergo colonoscopy at the research site and who are classified in category P2, P3 or P4.~2. Subjects who provide informed consent to participate in the trial~Exclusion Criteria:~1. Lack of understanding and/or participation due to illiteracy or inability to comprehend English or French~2. Subjects in category P3 who are there due to knowledge or suspicion of an inflammatory bowel disease~3. Previous history of cancer (any type) or active infection (as declared by the subject at the time of enrolment)~4. Currently participating (or participated within the previous 120 days) in an investigational therapeutic study (in case of interference of the drug with the immune system)~5. Subjects who underwent their colonoscopy and~   1. the colonoscopy preparation was judged insufficient~  2. the colonoscopy itself was judged insufficient or incomplete by the doctor~  3. the biopsy sample was lost and cancer could not be pathologically confirmed~  4. the colonoscopy detected an inflammatory bowel disease~6. Female who is pregnant, nursing, or of child-bearing potential while not practicing effective contraceptive methods.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Saved From COVID-19 - Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years,~2. Employment by New York Presbyterian Hospital~3. Clear assignment to areas of the hospital that involve patient contact and possible exposures for at least 2 days a week \>/= 8 hours a day~Exclusion Criteria:~1. Individuals who are taking CQ for other indications~2. New use of NSAIDs~3. High risk background medications not limited to immunosuppressive regimens, steroids, anti-B cell therapies, anti-cytokine therapies, chemotherapies, Janus Kinase (JAK)-inhibitors~4. Individuals with a history of retinopathy that would contraindicate the use of CQ~5. Known allergy to CQ or chloroquine~6. Known QT prolongation and torsades de point~7. Individuals who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CQ group (Type: EXPERIMENTAL): Participants will receive CQ supply for 3 months. Patients will receive a supply of 36 -- 250 mg tabs or placebo that will last 3 months (enough for taking two tabs of 250mg for every day for one week and then two tabs of 250mg for 1 day a week thereafter for study duration of 3 months). Subjects with severe GI intolerance can take 1 tablet of 250mg daily for the first week and 1 tablet per week for the remainder of the 3 month study duration. Patients will attend 1 in person visits (month 0) and an additional visit during month 3 if possible with the physician where they will be evaluated for safety assessments including vital signs, physical exams, blood collection, and assessment of endpoints. During month 1, 2, and 3 participants will be followed up regarding concomitant medications and adverse events over the phone call.
- Placebo group (Type: PLACEBO_COMPARATOR): Participants will receive placebo supply for 3 months. Patients will attend 1 in person visits (month 0) and an additional visit during month 3 if possible with the physician where they will be evaluated for safety assessments including vital signs, physical exams, blood collection, and assessment of endpoints. During month 1, 2, and 3 participants will be followed up regarding concomitant medications and adverse events over the phone call.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues